What the trial was testing
The LOTIS-2 enrolled 145 patients with lymphoma. The study was sponsored by ADC Therapeutics S.A. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
48% of patients with treatment-resistant lymphoma responded to this targeted antibody therapy.
The Lancet. Oncology · 2021 · NCT03589469
These findings — that nearly half saw their lymphoma shrink or disappear after other treatments failed — were published in the The Lancet. Oncology and represent the headline result of the study.
Researchers tracked outcomes across 145 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with lymphoma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This treatment is FDA-approved and available now for people with this type of blood cancer who have tried at least two other treatments. It's given through an IV every three weeks. Ask your doctor whether this therapy might be right for you, especially if other treatments haven't worked.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open lymphoma trials
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
This study assesses the quality of life in patients with cutaneous lymphoma diagnosis as it relates to their personal, clinical, and therapeutic information using the Skindex29 questionnaire and also assesses patients' understanding of their diagnosis and need for resources related to their care. Cutaneous lymphomas are a rare type of blood cancers (non-Hodgkin lymphoma) that present in the skin. The information gained from this study, may help researchers improve quality of life in cutaneous lymphoma patients.
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.